Mexico: Cannabis And Narcotics For Medicinal Use In Mexico

Last Updated: 13 March 2017
Article by Alejandro Luna, Alejandro Torres and Ingrid Ortiz

Cannabis and Narcotics for Medicinal use still have an uncertain status in Mexico. Regarding the medicinal use of cannabis there is still debate since the Mexican General Health Law still contains a provision that forbids activities and conducts in Mexico related with cannabis or its derivatives; with respect with other narcotics, there is also a prohibition within our Health Law. However, there are some precedents introducing the medicinal use of cannabis, and for other narcotics there are some approvals granted with our current legislation which have been in force for many years now.

The prohibition stablished in the Health Law mainly forbids plantation, cultivation, harvesting, elaboration, preparation, conditioning, acquisition, possession, trade, transportation in any form, prescription, supply, employment, use, consumption and, in general, any act related with narcotics or any products that contains them. The Health Law specifically prohibits prepared opium, for smoking, diacetylmorphine or heroin, its salts and preparations, cannabis sativa, indica and american or marijuana or opium poppy papaver somniferum, papaver bactreatum and erythroxilon novogratense or cocaine, in any form, derivatives or preparations. Additionally the Health Law stablishes a list of narcotics which approval is under the discretion of the Ministry of Health until they can be replaced in its therapeutic uses by other elements that, in their opinion, do not create dependency.

At the end of 2015, Mexican Supreme Court of Justice debated whether "recreational" use of cannabis should be authorized by the Federal Commission for Protection against Sanitary Risk (COFEPRIS) the Mexican Health Regulatory Agency.

Four members of a Mexican non-governmental organization (NGO) contested the refusal of a petition filed before COFEPRIS to plant, cultivate, prepare, possess and transport cannabis for "recreational" use. They argued in part that the basis of the refusal and the corresponding provisions of the Health Law violated the civil right to express one's personality and the rights of autonomy related to the human dignity that are recognized by the Mexican Constitution.

The District Court in charge of reviewing this Constitutional Action at the first stage dismissed the arguments. The NGO appealed, and due to the importance of the case, the appeal was taken up by the Mexican Supreme Court.

In brief, the Supreme Court Justices who decided the case declared certain articles of the Mexican General Health Law unconstitutional, as they foresee an extreme prohibition that attempts against these constitutional rights. The decision addressed that there is a minor health risk associated with cannabis, which is not severe and therefore does not require a strict prohibition like the one established by the related provisions of the Health Law.

The Supreme Court ordered COFEPRIS to issue the corresponding authorizations to these four members of the NGO, allowing them to plant, cultivate, prepare, possess and transport cannabis, but only for "recreational" use. The decision expressly excluded any act of commercialization, supply or any other activity that relates to disposal or distribution of cannabis. Finally, the Supreme Court's ruling considered that prohibiting the use of cannabis for "recreational" purposes is unconstitutional.

COFEPRIS complied with the decision on December 10, 2015, by granting to these four individuals the authorization to plant, cultivate, prepare, possess and transport cannabis for self-consumption on a "recreational" use, excluding any commercial activity. The case is significant, but the ruling has limited impact at the moment, as it is directed only to these four contesting individuals. Although highly persuasive, the decision does not constitute binding jurisprudence to other Courts of Law.

Despite the fact that the case was mainly focused to "recreational use" of cannabis the discussion among the Justices of the Mexican Supreme Court and the decision itself introduced the possibility of having approved clinical trials with cannabis, an eventual medicinal use of cannabis or pharmaceutical products with cannabis.

Notwithstanding the foregoing, at the time, there was another relevant case, wherein the importation and personal use of a drug with cannabidiol as an active ingredient was approved by COFEPRIS. Also, at the end of 2015, as a result of a constitutional action filed before a Federal District Court by the parents of a girl who suffered several epileptic seizures, in fact around 400 seizures, during a day, COFEPRIS was ordered to approve the importation and personal use of a drug with cannabis. The story behind the legal case moved our regulatory authorities, who showed they were willing to help by facilitating the importation of the medicine with cannabis, but also that they were open to discussion on the medicinal use of cannabis.

These precedents have made a great introduction to relevant topics such as the medical use of cannabis and other narcotics. They have set an interpretation of the "prohibitionist system" stablished in the Health Law stating that the Law actually does prohibit the "recreational" use of narcotics, including cannabis, but such state prohibition shall not apply to a medicinal use.

The decisions by the Supreme Court and other Federal Courts have had already considerable impact on the Mexican legal system as it relates to the use of this drug. Various levels of the Mexican Federal Government have begun a serious and formal debate regarding the recreational and medical use of cannabis; thus, other narcotics.

On April 21, 2016 the Mexican President Enrique Peña Nieto submitted a legislative proposal aimed to authorize cannabis for medicinal use. The Bill is aimed to authorize cannabis for medicinal use (personal use), including investigational activities and granting marketing authorizations for medicines which active ingredient is THC. The legislative proposal should be materialized by some modifications to the Health Law and the Federal Criminal Code. For this purpose, the Mexican Congress has created a Technical Committee designed for the eventual issuance of regulations regarding cannabis.

The proposal by the Mexican President was approved by the Senate on December 13, 2016. Although, the Bill is still pending for approval by the lower chamber of the Mexican Congress; considering the judicial precedents by the Mexican Supreme Court of Justice and other Federal Courts, there are great probabilities that the Bill is also approved by this chamber as well.

On the other hand, although there is still debate and the regulation is still under interpretation on case by case basis in most of the cases the "prohibitionist system" stablished in the General Health Law is applied.

Nevertheless, it is well known that there are approved pharmaceutical products which their active ingredient is a narcotic. Even, in one of the databases of the COFEPRIS' official website there are records of approved medicines with narcotics, such as Buprenorphine, Fentanyl, Sufentanil, Hydromorphone, Oxycodone, Tapentadol and Morphine. These are considered as narcotics in accordance to a list stated by a provision within the Health Law. Most of these substances are derived from opium considered by our Health Law as a narcotic, and broadly included in the prohibition. Furthermore, since 2006, COFEPRIS granted an approval for a medicine containing nabilone, which is a synthetic cannabinoid.

Considering the nature of such substances the prohibition should have been considered prior their approval, which did not happen. Therefore, the medicinal use was allowed under an exception to the rule, most probably due to the evidence of improvements and wellness that these substances provide to the patients.

In contrast, even though there is clinical evidence of the safety use of narcotics for medicinal use and that there are approved products using a therapeutic effect of a narcotics, any issue related to narcotics, it is still very sensitive in Mexico in all the levels of the government and society. Some of our authorities have spoken out against the medicinal use of cannabis or other narcotics in Mexico because they consider that narcotics represent a risk. They claim that our country does not have the required experience to govern and structure the legal frame to rule and enforce the use of narcotics and cannabis.

Although this approval of the Bill by the Senate and the precedents are a big step, we are only half way on having cannabis and other narcotics fully accepted and authorized for medicinal use in Mexico.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions